Clinical Research Of The Protective Effect And Mechanism Of Butylphthalide For Acute Ischemia Stroke

Objections: To investigate the changes of the soluble intercellular adhesion molecule-1 (sICAM-1), malondialdehyde(MDA), superoxide dismutase (SOD) and the neuron specific enolase(NSE) in patients with acute cerebral infarction and its clinical significance, and to further explore the protective effect of Butylphthalide and its possible mechanism.Methods: 60 cases of acute cerebral infarction were randomly divided into two groups, NBP group(30 cases) and routine medicine group(30 cases). The level of serum sICAM-1, MDA, activities of SOD and NSE were respectively measured by using two-layer antibody sandwich ELISA, colorimetric method and chemoluminescence ELISA on the 1st day, 7th day, 14th day after hospitalization respectively. 20 cases healthy people component control group .The scores of clinical neurological deficits in patients with ACI were evaluated on the 1st day and 14th day after hospitalization, and evaluated the therapeutic effects.Results:â‘ The levels of serum sICAM-1, MDA and NSE in NBP group and routine medicine group on the 1 st day after hospitalization were significantly higher than those in the controls, and the level of activities of SOD was obviously lower than that in the controls(P<0.01).â‘¡There were no significant difference between NBP group and routine medicine group in the levels of serum sICAM-1, MDA, SOD and NSE on the 1st day after hospitalization(P>0.05); The level of serum sICAM-1, MDA and NSE in NBP group were significant lower, the level of serum SOD in NBP group were significant higher than those in routine medicine group(P<0.05); The level of serum sICAM-1, SOD, MDA and NSE in two groups decreased or increased gradually on the 7th ,14th day(P<0.01);.â‘¢There were no significant difference between NBP group and routine medicine group in the scores of clinical neurological deficits (P>0.05); The scores of two groups decreased on the 14th day after hospitalization (P<0.01), but NBP group were much less than those of routine medicine group(P<0.05); Clinical effective rate in NBP group was obviously higher than that in routine medicine group (P<0.05).Conclusion: Butylphthalide can decrease the levels of serum sICAM-1 in patients with acute cerebral infarction, inhibit the express of adhesion molecules and reduce the extent of inflammatory injure in the course of cerebral ischemia. Butylphthalide can decrease the level of serum MDA and increase serum SOD activity, may inhibit formation of lipid peroxide and free radical, and subsides oxidative. Butylphthalide can decrease the level of serum NSE, improve clinical neurological deficits, and protect impaired neuron. It is safe and effective to use Butylphthalide in treatment of acute ischemic stroke.